[HTML][HTML] Breast cancer cell-derived extracellular vesicles promote CD8+ T cell exhaustion via TGF-β type II receptor signaling
F Xie, X Zhou, P Su, H Li, Y Tu, J Du, C Pan… - Nature …, 2022 - nature.com
Cancer immunotherapies have shown clinical success in various types of tumors but the
patient response rate is low, particularly in breast cancer. Here we report that malignant …
patient response rate is low, particularly in breast cancer. Here we report that malignant …
[HTML][HTML] Breast cancer cell-derived extracellular vesicles promote CD8+ T cell exhaustion via TGF-β type II receptor signaling
F Xie, X Zhou, P Su, H Li, Y Tu, J Du, C Pan… - Nature …, 2022 - ncbi.nlm.nih.gov
Cancer immunotherapies have shown clinical success in various types of tumors but the
patient response rate is low, particularly in breast cancer. Here we report that malignant …
patient response rate is low, particularly in breast cancer. Here we report that malignant …
Breast cancer cell-derived extracellular vesicles promote CD8+ T cell exhaustion via TGF-β type II receptor signaling
F Xie, X Zhou, P Su, H Li, Y Tu, J Du, C Pan… - Nature …, 2022 - ideas.repec.org
Cancer immunotherapies have shown clinical success in various types of tumors but the
patient response rate is low, particularly in breast cancer. Here we report that malignant …
patient response rate is low, particularly in breast cancer. Here we report that malignant …
Breast cancer cell-derived extracellular vesicles promote CD8 (+) T cell exhaustion via TGF-beta type II receptor signaling
F Xie, XX Zhou, P Su, HY Li… - Nature …, 2022 - scholarlypublications …
Understanding the factors that hamper immune therapy in breast cancer may increase the
range of patients who benefit. Here authors show that breast cancer cells produce and …
range of patients who benefit. Here authors show that breast cancer cells produce and …
Breast cancer cell-derived extracellular vesicles promote CD8+ T cell exhaustion via TGF-β type II receptor signaling.
F Xie, X Zhou, P Su, H Li, Y Tu, J Du, C Pan… - Nature …, 2022 - europepmc.org
Cancer immunotherapies have shown clinical success in various types of tumors but the
patient response rate is low, particularly in breast cancer. Here we report that malignant …
patient response rate is low, particularly in breast cancer. Here we report that malignant …
Breast cancer cell-derived extracellular vesicles promote CD8+ T cell exhaustion via TGF-β type II receptor signaling.
F Xie, X Zhou, P Su, H Li, Y Tu, J Du… - Nature …, 2022 - search.ebscohost.com
Cancer immunotherapies have shown clinical success in various types of tumors but the
patient response rate is low, particularly in breast cancer. Here we report that malignant …
patient response rate is low, particularly in breast cancer. Here we report that malignant …
Breast cancer cell-derived extracellular vesicles promote CD8+ T cell exhaustion via TGF-β type II receptor signaling
F Xie, X Zhou, P Su, H Li, Y Tu, J Du… - Nature …, 2022 - ui.adsabs.harvard.edu
Cancer immunotherapies have shown clinical success in various types of tumors but the
patient response rate is low, particularly in breast cancer. Here we report that malignant …
patient response rate is low, particularly in breast cancer. Here we report that malignant …
Breast cancer cell-derived extracellular vesicles promote CD8+ T cell exhaustion via TGF-β type II receptor signaling
F Xie, X Zhou, P Su, H Li, Y Tu, J Du… - Nature …, 2022 - pubmed.ncbi.nlm.nih.gov
Cancer immunotherapies have shown clinical success in various types of tumors but the
patient response rate is low, particularly in breast cancer. Here we report that malignant …
patient response rate is low, particularly in breast cancer. Here we report that malignant …
Breast cancer cell-derived extracellular vesicles promote CD8+ T cell exhaustion via TGF-β type II receptor signaling
F Xie, X Zhou, P Su, H Li, Y Tu, J Du… - Nature …, 2022 - econpapers.repec.org
Cancer immunotherapies have shown clinical success in various types of tumors but the
patient response rate is low, particularly in breast cancer. Here we report that malignant …
patient response rate is low, particularly in breast cancer. Here we report that malignant …